Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$0.72 -12.3%	$0.40	$0.30 ▼ $3.33	$16.91M	-1.38	1.60 million shs	11.78 million shs
ADXN Addex Therapeutics	$8.90 +6.0%	$8.05	$6.51 ▼ $13.27	$8.98M	1.62	94,360 shs	1,390 shs
BCLI Brainstorm Cell Therapeutics	$1.21 +1.7%	$1.11	$0.72 ▼ $6.60	$9.61M	0.24	375,209 shs	287,445 shs
SXTC China SXT Pharmaceuticals	$1.89 +1.6%	$1.80	$0.95 ▼ $11.92	$29.91M	1.11	1.19 million shs	53,178 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	0.00%	+118.12%	+73.83%	+70.05%	-68.00%
ADXN Addex Therapeutics	0.00%	+9.68%	+10.29%	+12.38%	+9.14%
BCLI Brainstorm Cell Therapeutics	0.00%	+2.54%	-2.42%	-14.18%	-79.84%
SXTC China SXT Pharmaceuticals	0.00%	-7.35%	+21.15%	-31.02%	-78.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACXP Acurx Pharmaceuticals	2.8438 of 5 stars	3.5	5.0	0.0	2.1	1.7	0.0
ADXN Addex Therapeutics	2.3663 of 5 stars	3.5	5.0	0.0	0.0	0.8	0.6
BCLI Brainstorm Cell Therapeutics	3.921 of 5 stars	3.5	2.0	4.7	2.2	0.8	0.6
SXTC China SXT Pharmaceuticals	0.4267 of 5 stars	0.0	3.0	0.0	1.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXP Acurx Pharmaceuticals	3.00	Buy	$8.00	1,011.11% Upside
ADXN Addex Therapeutics	3.00	Buy	$30.00	237.27% Upside
BCLI Brainstorm Cell Therapeutics	3.00	Buy	$30.00	2,379.34% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, ADXN, BCLI, and ACXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/15/2025	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$8.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
ADXN Addex Therapeutics	$460K	20.50	N/A	N/A	$10.37 per share	0.86
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
SXTC China SXT Pharmaceuticals	$1.93M	15.50	N/A	N/A	$243.66 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXP Acurx Pharmaceuticals	-$14.10M	-$0.70	N/A	N/A	N/A	N/A	-526.78%	-223.78%	8/8/2025 (Estimated)
ADXN Addex Therapeutics	$8.02M	-$0.34	N/A	∞	N/A	1,717.88%	-61.65%	-49.42%	9/1/2025 (Estimated)
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$3.36	N/A	N/A	N/A	N/A	N/A	-519.50%	8/13/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SXTC, ADXN, BCLI, and ACXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	BCLI Brainstorm Cell Therapeutics	-$0.38	-$0.45	-$0.07	-$0.45	N/A	N/A
5/12/2025	Q1 2025	ACXP Acurx Pharmaceuticals	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXP Acurx Pharmaceuticals	N/A	1.93	1.93
ADXN Addex Therapeutics	N/A	4.42	4.42
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
SXTC China SXT Pharmaceuticals	0.01	1.40	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXP Acurx Pharmaceuticals	11.53%
ADXN Addex Therapeutics	16.14%
BCLI Brainstorm Cell Therapeutics	14.33%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
ACXP Acurx Pharmaceuticals	26.00%
ADXN Addex Therapeutics	15.00%
BCLI Brainstorm Cell Therapeutics	11.15%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXP Acurx Pharmaceuticals	3	23.48 million	17.38 million	Optionable
ADXN Addex Therapeutics	30	1.06 million	901,000	Not Optionable
BCLI Brainstorm Cell Therapeutics	40	7.94 million	7.05 million	Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	15.20 million	Not Optionable

SXTC, ADXN, BCLI, and ACXP Headlines

Recent News About These Companies

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16, 2025 | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.com

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.com

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 2, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock creates opportunities due to its volume and complexity

May 21, 2024 | bovnews.com

JAGX, BSGM and SXTC among mid-day movers

April 16, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, ADXN, BCLI, and ACXP Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

$0.72 -0.10 (-12.27%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$0.68 -0.03 (-4.86%)

As of 06/18/2025 07:59 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Addex Therapeutics NASDAQ:ADXN

$8.90 +0.51 (+6.02%)

Closing price 06/18/2025 03:00 PM Eastern

Extended Trading

$8.85 -0.04 (-0.51%)

As of 06/18/2025 06:39 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.21 +0.02 (+1.68%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.22 +0.01 (+0.41%)

As of 06/18/2025 07:49 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.89 +0.03 (+1.61%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.86 -0.03 (-1.80%)

As of 06/18/2025 07:56 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time